Sea Buckthorn Seed Lipid Extract HIPPOCOR® Clinical study
In 2021, the University of Latvia Institute of Cardiology and Regenerative Medicine started a clinical trial of the sea buckthorn seed lipid extract HIPPOCOR® (Omega-3, 6, 9 fatty acids from sea buckthorn) to assess safety and efficacy. In this trial, patients with residual risk of cardiovascular diseases* were included. As part of the study, in addition to standard medical therapy and medication use, the included patients took 2000 mg (two capsules) of HIPPOCOR® dietary supplement for at least 3 months.
Initial results of the study indicated that the product:
- is safe for use (no observed adverse events);
- reduces systolic blood pressure, low-density lipoprotein cholesterol (LDL-C), and glucose levels in the blood;
- promotes metabolism.
References:
1 Sea Buckthorn Seed Oils as a Novel Omega 3 Source for Coronary Heart Disease Patients with Residual Risk, Iveta Mintale et al Medicina (Kaunas) 2022;58(Supplement 1);
2 How to Reduce the Residual Cardiovascular Risk: Focus on Phytosterols, Kristaps Erglis et al Medicina (Kaunas) 2022;58 (Supplement 1).